These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33446406)

  • 1. Slaying SARS-CoV-2 One (Single-domain) Antibody at a Time.
    Czajka TF; Vance DJ; Mantis NJ
    Trends Microbiol; 2021 Mar; 29(3):195-203. PubMed ID: 33446406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-domain antibodies against SARS-CoV-2 RBD from a two-stage phage screening of universal and focused synthetic libraries.
    Chen F; Liu Z; Kang W; Jiang F; Yang X; Yin F; Zhou Z; Li Z
    BMC Infect Dis; 2024 Feb; 24(1):199. PubMed ID: 38350843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.
    Chi X; Liu X; Wang C; Zhang X; Li X; Hou J; Ren L; Jin Q; Wang J; Yang W
    Nat Commun; 2020 Sep; 11(1):4528. PubMed ID: 32913273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.
    Yuan TZ; Garg P; Wang L; Willis JR; Kwan E; Hernandez AGL; Tuscano E; Sever EN; Keane E; Soto C; Mucker EM; Fouch ME; Davidson E; Doranz BJ; Kailasan S; Aman MJ; Li H; Hooper JW; Saphire EO; Crowe JE; Liu Q; Axelrod F; Sato AK
    MAbs; 2022; 14(1):2002236. PubMed ID: 34967699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2.
    Tang Q; Owens RJ; Naismith JH
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike.
    Schoof M; Faust B; Saunders RA; Sangwan S; Rezelj V; Hoppe N; Boone M; Billesbølle CB; Puchades C; Azumaya CM; Kratochvil HT; Zimanyi M; Deshpande I; Liang J; Dickinson S; Nguyen HC; Chio CM; Merz GE; Thompson MC; Diwanji D; Schaefer K; Anand AA; Dobzinski N; Zha BS; Simoneau CR; Leon K; White KM; Chio US; Gupta M; Jin M; Li F; Liu Y; Zhang K; Bulkley D; Sun M; Smith AM; Rizo AN; Moss F; Brilot AF; Pourmal S; Trenker R; Pospiech T; Gupta S; Barsi-Rhyne B; Belyy V; Barile-Hill AW; Nock S; Liu Y; Krogan NJ; Ralston CY; Swaney DL; García-Sastre A; Ott M; Vignuzzi M; ; Walter P; Manglik A
    Science; 2020 Dec; 370(6523):1473-1479. PubMed ID: 33154106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization.
    Zebardast A; Hosseini P; Hasanzadeh A; Latifi T
    Mol Biol Rep; 2022 Jan; 49(1):647-656. PubMed ID: 34648139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Human Single-Domain Antibodies against SARS-CoV-2.
    Wu Y; Li C; Xia S; Tian X; Kong Y; Wang Z; Gu C; Zhang R; Tu C; Xie Y; Yang Z; Lu L; Jiang S; Ying T
    Cell Host Microbe; 2020 Jun; 27(6):891-898.e5. PubMed ID: 32413276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes.
    Mikolajek H; Weckener M; Brotzakis ZF; Huo J; Dalietou EV; Le Bas A; Sormanni P; Harrison PJ; Ward PN; Truong S; Moynie L; Clare DK; Dumoux M; Dormon J; Norman C; Hussain N; Vogirala V; Owens RJ; Vendruscolo M; Naismith JH
    Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2205412119. PubMed ID: 35858383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro.
    Gauhar A; Privezentzev CV; Demydchuk M; Gerlza T; Rieger J; Kungl AJ; Walsh FS; Rutkowski JL; Stocki P
    FASEB J; 2021 Nov; 35(11):e21970. PubMed ID: 34637549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
    Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
    Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
    Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A
    J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
    Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M
    Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
    Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparing for the Future - Nanobodies for Covid-19?
    Sasisekharan R
    N Engl J Med; 2021 Apr; 384(16):1568-1571. PubMed ID: 33826817
    [No Abstract]   [Full Text] [Related]  

  • 18. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.
    Tian X; Li C; Huang A; Xia S; Lu S; Shi Z; Lu L; Jiang S; Yang Z; Wu Y; Ying T
    Emerg Microbes Infect; 2020; 9(1):382-385. PubMed ID: 32065055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
    Piccoli L; Park YJ; Tortorici MA; Czudnochowski N; Walls AC; Beltramello M; Silacci-Fregni C; Pinto D; Rosen LE; Bowen JE; Acton OJ; Jaconi S; Guarino B; Minola A; Zatta F; Sprugasci N; Bassi J; Peter A; De Marco A; Nix JC; Mele F; Jovic S; Rodriguez BF; Gupta SV; Jin F; Piumatti G; Lo Presti G; Pellanda AF; Biggiogero M; Tarkowski M; Pizzuto MS; Cameroni E; Havenar-Daughton C; Smithey M; Hong D; Lepori V; Albanese E; Ceschi A; Bernasconi E; Elzi L; Ferrari P; Garzoni C; Riva A; Snell G; Sallusto F; Fink K; Virgin HW; Lanzavecchia A; Corti D; Veesler D
    Cell; 2020 Nov; 183(4):1024-1042.e21. PubMed ID: 32991844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction.
    Ahmad J; Jiang J; Boyd LF; Zeher A; Huang R; Xia D; Natarajan K; Margulies DH
    J Biol Chem; 2021 Oct; 297(4):101202. PubMed ID: 34537245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.